FREE Daily Stock Alerts From Stock-PR.com
Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM’s diagnostic test, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, PWRM’s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of PWRM, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
Newell Rubbermaid Inc. (NYSE:NWL)
NWL announced on September 30, 2010 the latest innovation from its trusted Irwin® Vise-Grip brand. Traditional locking pliers are prone to slipping unless a significant amount of pressure is applied. Irwin Vise-Grip Curved Jaw (NYSE:CR) Locking Pliers feature a unique self-energizing lower jaw that delivers three times more gripping power than traditional locking pliers, with absolutely no slipping or stripping.
NWL designs, manufactures, sources, packages, and distributes consumer and commercial products. NWL operates in three segments: Home & Family; Office Products; and Tools, Hardware & Commercial Products. The Home & Family segment offers infant and juvenile products, such as car seats, strollers, highchairs, and playards; gourmet cookware, bakeware, cutlery, small kitchen electrics, and kitchen gadgets and utensils; hair care accessories and grooming products; cabinet hardware, drapery hardware, and window treatments; and indoor/outdoor organization, food storage, and home storage products.
Denbury Resources Inc. (NYSE:DNR)
DNR Oil and gas company said on Tuesday October 12, 2010 that it agreed to sell assets in East Texas and in Haynesville, La., for $217.5 million. Denbury said the buyer is a privately held oil and gas company. The sale will close in 30 to 45 days. DNR will terminate some of its 2010 and 2011 natural gas hedges as a result of the sale, and it expects to get $10 million to $15 million from the terminations.
DNR engages in the acquisition, development, operation, and exploration of oil and natural gas properties in the Gulf Coast region of the United States primarily in Mississippi, Louisiana, Texas, and Alabama. It also owns carbon dioxide (CO2) reserves in the east of the Mississippi River and sells CO2 to third party industrial users.
UBS AG (NYSE:UBS)
UBS said on October 14, 2010 it won't pursue previous management in court for their role in hefty losses suffered by the Swiss bank or for failing to prevent illegal practices in its dealings with wealthy U.S. clients. The Zurich-based bank lacks what one expert termed "the smoking gun" to make a plausible legal case against executives such as Marcel Ospel, chairman until 2008, and doesn't want to get involved in a lengthy, costly and messy legal skirmish, Chairman Kaspar Villiger said Thursday. UBS is also wary of endangering its position in continuing U.S. proceedings, including one looking into alleged bid-rigging and price-fixing.
UBS, a financial services firm, provides wealth management, asset management, and investment banking services to private, corporate, and institutional clients worldwide. UBS also involves in retail and commercial banking in Switzerland.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.